|
2025
|
G/S
|
Providing medical information, namely, consumer product information regarding medical products to... |
|
|
G/S
|
Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, be... |
|
|
G/S
|
Providing health information to patients, caregivers and health care professionals; providing hea... |
|
2024
|
Invention
|
Crystalline forms of c21h22cl2n4o2.
The present invention provides crystalline forms of a compou... |
|
|
Invention
|
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof.
Provi... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cystic fibrosis. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cystic
fibrosis. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cystic fibrosis |
|
|
Invention
|
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy.
Composition... |
|
|
Invention
|
Differentiation of pancreatic endocrine cells.
Disclosed herein are compositions and methods rel... |
|
|
Invention
|
Differentiation of pancreatic endocrine cells. Disclosed herein are compositions and methods rela... |
|
|
Invention
|
Cell therapy for diabetes.
Disclosed herein are methods of treating a subject having diabetes wi... |
|
|
Invention
|
Cell therapy for diabetes. Disclosed herein are methods of treating a subject having diabetes wit... |
|
|
Invention
|
Macroencapsulation device implantation and transport system and methods.
Macroencapsulation impl... |
|
|
Invention
|
Gcn2 inhibitors and uses thereof.
The present invention provides compounds, compositions thereof... |
|
|
Invention
|
Urea-containing agonists of orexin receptor type 2. Disclosed are compounds, compositions, and me... |
|
|
Invention
|
Materials and methods for treatment of duchenne muscular dystrophy.
The present application prov... |
|
|
Invention
|
Complement factor i-related compositions and methods.
Provided herein are Complement Factor I (C... |
|
|
Invention
|
Complement factor-i formulations.
Provided herein are pharmaceutically acceptable formulations c... |
|
|
Invention
|
Inhibitors of apol1 and methods of using same.
The disclosure provides at least one entity chose... |
|
|
Invention
|
Affinity purification methods for adeno associated viruses (aavs). Provided herein are isolated p... |
|
|
Invention
|
Methods for directing lipid nanoparticles in vivo. Compositions and methods for enhancing payload... |
|
|
Invention
|
Compact proteins. Disclosed herein are compositions of compact proteins such as compact nucleobas... |
|
|
Invention
|
Stem cell derived pancreatic islet differentiation.
Disclosed herein are compositions and method... |
|
|
G/S
|
Providing health information to patients and caregivers; providing health care information; provi... |
|
|
Invention
|
Hypoimmune cells.
Disclosed herein are compositions and methods related to isolated cells (e.g.,... |
|
|
G/S
|
Educational services, namely, providing classes, seminars, and workshops in the fields of medicat... |
|
|
Invention
|
Materials and methods for treatment of hemoglobinopathies.
Materials and methods for treating a ... |
|
|
Invention
|
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy.
Compositi... |
|
|
Invention
|
Islet cell manufacturing compositions and methods of use.
Disclosed herein are compositions and ... |
|
|
Invention
|
Macroencapsulation devices including immunomodulatory compounds. Macroencapsulation devices and t... |
|
|
Invention
|
Gene editing of regulatory elements.
Compositions and methods for disrupting and/or excising reg... |
|
|
Invention
|
Biaryl amide-containing agonists of orexin receptor type 2. Disclosed are compounds, compositions... |
|
|
G/S
|
Pharmaceuticals and medicines for the treatment of cystic
fibrosis, pain, sickle cell disease, b... |
|
2023
|
Invention
|
Re-aggregation of stem cell-derived pancreatic beta cells.
The present application discloses cel... |
|
|
G/S
|
Pharmaceuticals and medical treatment products in the field of diabetes; cell therapy products fo... |
|
|
G/S
|
Pharmaceuticals and medical treatments in the field of diabetes; cell therapy products for medica... |
|
|
G/S
|
Pharmaceuticals and medical treatments in the field of
diabetes; cell therapy products for medic... |
|
|
G/S
|
Pharmaceuticals and medical treatment products in the field
of diabetes; cell therapy products f... |
|
|
G/S
|
Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diabe... |
|
|
G/S
|
Pharmaceutical preparations for treating diabetes; medical
treatments in the nature of anti-diab... |
|
|
Invention
|
Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels. Provided ... |
|
|
Invention
|
Substituted tetrahydrofurans as modulators of sodium channels. Compounds, and pharmaceutically ac... |
|
|
Invention
|
Substituted macrocyclic amine modulators of orexin receptor 2. Disclosed are compounds, compositi... |
|
|
Invention
|
Crystalline forms of cftr modulators.
Crystalline forms of Compound I:
Crystalline forms of Co... |
|
|
Invention
|
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels.
Com... |
|
|
Invention
|
Modulators of alpha-1 antitrypsin.
The disclosure provides compounds useful for treating alpha-1... |
|
|
Invention
|
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, m... |
|
|
Invention
|
Methods of treating apol-1 dependent focal segmental glomerulosclerosis.
This application descri... |
|
|
G/S
|
medical and scientific research; medical and scientific research in the field of gene therapy; me... |
|
|
Invention
|
Cell housing device.
The present disclosure provides a cell housing device and a method of manuf... |
|
|
Invention
|
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9.
Composit... |
|
|
Invention
|
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9.
Composi... |
|
|
G/S
|
Providing on-line non-downloadable software for use by healthcare professionals to view and acces... |
|
|
G/S
|
Providing health information in the field of sickle cell disease; providing health care informati... |
|
|
Invention
|
Pharmaceutical composition and administrations thereof. The present invention relates to pharmace... |
|
|
Invention
|
Processes for making modulators of cystic fibrosis transmembrane conductance regulator. The discl... |
|
2022
|
Invention
|
Stem cell differentiation and chemical compounds.
Disclosed herein are compositions and methods ... |
|
|
Invention
|
Macroencapsulation devices.
Macroencapsulation devices and related methods of manufacture are de... |
|
|
Invention
|
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channel... |
|
|
Invention
|
Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels.
Compounds of formul... |
|
|
Invention
|
Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels.
Compound... |
|
|
Invention
|
Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phe... |
|
|
Invention
|
Stem cell differentiation and polymers.
Disclosed herein are compositions and methods related to... |
|
2021
|
Invention
|
Enhanced differentiation of beta cells.
Provided herein are, inter alia, compositions and method... |
|
|
Invention
|
In vitro differentiation of pancreatic endocrine cells.
Disclosed herein are compositions and me... |
